These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 33710360)

  • 1. [Risk assessment in osteoporosis : Time-tested and new approaches].
    Thomasius F; Bühring B
    Internist (Berl); 2021 May; 62(5):463-473. PubMed ID: 33710360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnosing osteoporosis: what is new in the 2014 DVO guideline?].
    Pfeilschifter J
    Dtsch Med Wochenschr; 2015 Nov; 140(22):1667-71. PubMed ID: 26536643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vertebral fracture assessment by dual-energy X-ray absorptiometry along with bone mineral density in the evaluation of postmenopausal osteoporosis.
    Shetty S; John B; Mohan S; Paul TV
    Arch Osteoporos; 2020 Feb; 15(1):25. PubMed ID: 32095943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.
    Siris ES; Baim S; Nattiv A
    Postgrad Med; 2010 Jan; 122(1):82-90. PubMed ID: 20107292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [DVO guideline 2006. What changes have there been in the diagnosis, prevention and treatment of osteoporosis?].
    Fassbender WJ; Stumpf UC
    Z Rheumatol; 2006 Sep; 65(5):364-6, 368-9. PubMed ID: 16947038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and predictors of fractures associated with osteoporosis.
    Lips P
    Am J Med; 1997 Aug; 103(2A):3S-8S; discussion 8S-11S. PubMed ID: 9302892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA.
    Wright NC; Saag KG; Dawson-Hughes B; Khosla S; Siris ES
    Osteoporos Int; 2017 Apr; 28(4):1225-1232. PubMed ID: 27966104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
    Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
    J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New DVO guideline for osteoporosis management 2014 and its importance for trauma surgeons].
    Neuerburg C; Stumpf U; Schmidmaier R; Kammerlander C; Pfeilschifter J; Mutschler W; Böcker W
    Unfallchirurg; 2015 Nov; 118(11):905-12. PubMed ID: 26446723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis.
    Kaji H; Yamauchi M; Chihara K; Sugimoto T
    Endocr J; 2006 Feb; 53(1):27-34. PubMed ID: 16543669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment.
    Feldstein AC; Nichols GA; Elmer PJ; Smith DH; Aickin M; Herson M
    J Bone Joint Surg Am; 2003 Dec; 85(12):2294-302. PubMed ID: 14668497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fracture thresholds in osteoporosis: implications for hormone replacement treatment.
    Ryan PJ; Blake GM; Fogelman I
    Ann Rheum Dis; 1992 Sep; 51(9):1063-5. PubMed ID: 1417138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis Clinical Guideline. South African Medical Association--Osteoporosis Working Group.
    Hough S
    S Afr Med J; 2000 Sep; 90(9 Pt 2):907-44. PubMed ID: 11081144
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.